NF-kappa B Inhibitors – Pipeline Insight, 2020

DelveInsight’s, “NF-kappa B Inhibitors – Pipeline Insight, 2020,” report provides comprehensive insights about 90+ companies and 90+ pipeline drugs based on NF-kappa B Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
• Global coverage
NF-kappa B Inhibitors Understanding
NF-kappa B Inhibitors: Overview
The nuclear factor-κB (NF-κB) signaling pathway plays a major role in the development, maintenance, and progression of most chronic diseases. NF-κB controls the expression of genes involved in a number of physiological responses, including immune inflammatory responses, acute-phase inflammatory responses, oxidative stress responses, cell adhesion, differentiation, and apoptosis. Recent studies have suggested that NF-κB dysregulation is associated with many diseases including AIDS, atherosclerosis, asthma, arthritis, diabetes, inflammatory bowel disease, stroke, muscle wasting and viral infections. Mounting evidence indicates that NF-kB acts as a link between inflammation and cancer progression, making NF-κB essential to and a potential drug target in hematological malignancies and solid tumors. NF-κB was first identified in 1986 by Sen and Baltimore in the nucleus bound to an enhancer element of the immunoglobulin kappa light chain gene in B cells. It is now known to be ubiquitous in nature present in all the cell types and is evolutionary conserved. It belongs to the family of Rel proteins that includes c-Rel, RelA (p65), RelB, NF-κB1 (p50 and its precursor p105), and NF-κB2 (p52 and its precursor p100) all of which can form hetero- or homodimers.
NF-kappa B Inhibitors Emerging Drugs Chapters
This segment of the NF-kappa B Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
NF-kappa B Inhibitors Emerging Drugs
• AMG 0101: AnGes MG
AMG 0101 is being developed by AnGes MG for the treatment of Atopic dermatitis. It is currently in phase III stage of development.

• CXA-10: Complexa
CXA-10 is an oral nitrated fatty acid compound that acts through a constellation of actions including:
• Upregulation of Nrf2 pathways, a key pro-reparative and metabolic pathway
• Inhibition of NF-Kappa B and TLR4, key drivers of inflammatory molecules and pathways
• Inhibition of Xanthine Oxidoreductase, a key intracellular producer of Reactive Oxygen Species add that result in cellular oxidative stress
• Increasing the expression of heat shock proteins, which act as chaperones during cellular stress to restore cellular homeostatic mechanisms

• ACT001: Accendatech
ACT001 is an investigational product currently finished testing in phase I clinical studies. ACT001 is a drug designed and developed by Accendatech specifically used to target brain tumor for treatment of GBM and DIPG.
Further product details are provided in the report……..
NF-kappa B Inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different NF-kappa B Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
• Major Players in NF-kappa B Inhibitors
There are approx. 90+ key companies which are developing the therapies based on NF-kappa B Inhibitors. The companies which have their drug candidate based on NF-kappa B Inhibitors in the most advanced stage, i.e. phase III include AnGes MG and others
• Phases
DelveInsight’s report covers around 90+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage products (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

• Route of Administration
NF-kappa B Inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Oral
• Parenteral
• Subcutaneous
• Topical.
• Molecule Type
Products have been categorized under various Molecule types such as
• Gene therapies
• Small molecule
• Vaccines
• Polymers
• Peptides
• Monoclonal antibodies

• Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

NF-kappa B Inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses NF-kappa B Inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging NF-kappa B Inhibitors drugs.

Report Highlights
• The companies and academics are working to assess challenges and seek opportunities that could influence NF-kappa B Inhibitors R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
• In October 2020, Catabasis has stopped development of edasalonexent as phase III PolarisDMD trial of edasalonexent in Duchenne muscular dystrophy (DMD) did not meet the primary endpoint, which was a change from baseline in the North Star Ambulatory Assessment (NSAA) over one year of edasalonexent compared to placebo.
• In October 2019, The Company’s lead candidate, CXA-10, received orphan drug designation from the US Food and Drug Administration (FDA) for the treatment of pulmonary arterial hypertension (PAH).
NF-kappa B Inhibitors Report Insights
• NF-kappa B Inhibitors Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs
NF-kappa B Inhibitors Report Assessment
• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions
• What are the current treatment options available based on the NF-kappa B Inhibitors?
• How many companies are developing therapies by working on NF-kappa B Inhibitors?
• What are the principal therapies developed by these companies in the industry?
• How many therapies are developed by each company for NF-kappa B Inhibitors to treat disease condition?
• How many emerging therapies are in early-stage, mid-stage, and late stage of development for NF-kappa B Inhibitors?
• Out of total pipeline products, how many therapies are given as a monotherapy and in combination with other treatments?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the NF-kappa B Inhibitors therapies?
• Which are the dormant and discontinued products and the reasons for the same?
• What is the unmet need for current therapies developed based on this mechanism of action?
• What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for NF-kappa B Inhibitors and their status?
• What are the results of the clinical studies and their safety and efficacy?
• What are the key designations that have been granted for the emerging therapies for NF-kappa B Inhibitors?
• How many patents are granted and pending for the emerging therapies of NF-kappa B Inhibitors?
Key Players
• AnGes MG
• Complexa
• Accendatech
• Serenex
• OncoViRx
• Novo Nordisk
• Profectus Biosciences
• Mitsubishi Tanabe Pharma
• ImmuneTarget
• Merck Serono
• EntreChem
• Link Health Group

Key Products
• AMG 0101
• CXA-10
• ACT001
• Research programme: NF-kappa B inhibitors
• Research programme: I-kappa B kinase/NF-kappa B inhibitors
• Research programme: NF-kappa-B pathway inhibitors
• IT 901
• AS 602868
• EC 70124
• LH 025